Moderna shares jump after late-stage data for personalized mRNA melanoma vaccine with Merck’s Keytruda

Moderna’s shares rose sharply after the company and its partner, Merck & Co, said a personalized mRNA cancer vaccine called intismeran showed positive results in a late-stage study when used with Merck’s immunotherapy Keytruda.

According to the report carried by Proactive Investors, the companies said the combination slowed melanoma recurrence and reduced disease spread, a set of outcomes that investors typically treat as a key announcement of clinical benefit in oncology trials.

Intismeran is described in the report as a personalized mRNA cancer vaccine, meaning it is tailored to an individual patient’s tumor-related targets rather than being a one-size-fits-all shot. Moderna has positioned this approach as a way to train the immune system against cancers by using mRNA instructions specific to a patient’s disease.

The companies’ announcement also highlighted the pairing with Keytruda. Keytruda, Merck’s anti-PD-1 therapy, is designed to help the immune system recognize and attack tumors. In combination strategies, sponsors often aim to use an immunotherapy to “release the brakes” on immune responses while a vaccine component helps direct those responses toward cancer-related targets.

The report said the trial results related specifically to melanoma, a skin cancer where recurrence and metastatic spread are major drivers of patient outcomes and a frequent focus of late-stage endpoints.

While the headline outcome was described as slowing recurrence and spread, the report did not provide in-line details such as the study’s name, the exact patient population, the time horizon for follow-up, or the magnitude of effect. It also did not specify whether the results met predefined statistical thresholds for primary or secondary endpoints.

For Moderna, the update represents another high-profile checkpoint for its mRNA oncology strategy, which relies on its ability to rapidly generate personalized vaccine designs and deliver them at scale. For Merck, the finding continues a broader push to combine Keytruda with therapies that may improve response durability or prevent relapse.

Investors and clinicians will likely look next for additional disclosures, including full trial reporting on endpoint definitions, safety and tolerability, and how the benefits may vary by subgroup. Without more granular data, it remains difficult to assess the strength and clinical durability of the observed effect.